CD4 and metabolic dysfunction-associated steatotic liver disease: 3.2. SP16 Treatment during Late-Stage NAFLD Resulted in the Modulation of CD4+ Th Subsets without Affecting the Overall Immunological Pattern or Inhibiting HCC